Heartseed, World's First Clinical Trial of Catheter Administration of iPSC-Derived Cardiomyocyte Spheroids: First Patient Dosed
Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company, today announced the successful dosing of the first patient in its domestic Phase I/II EMERALD study of HS-005, allogeneic iPS cell-derived cardiomyocyte spheroids administered via catheter, targeting severe heart failure caused by ischemic heart disease or dilated cardiomyopathy.
Heartseed Succeeds in Stable Production of High Purity Cardiomyocytes Using iPS Cells from I Peace, A Major Step Forward in Advancing Autologous Cardiac Regenerative Medicine
Heartseed Inc. ("Heartseed"), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure and I Peace Inc. ("I Peace"), a leading GMP cell CDMO in Palo Alto, California, have collaborated to generate cardiomyocytes using multiple donor-derived iPS cell lines produced by I Peace and Heartseed's proprietary cardiomyocytes differentiation and purification methods. As a result, Heartseed has successfully produced high-purity cardiomyocytes consistently from all iPS cell lines used in this study. This achievement marks a significant step forward in the realization of autologous cardiac regenerative medicine, which uses iPS cells obtained from the patient's own cells.
Heartseed Announces the Presentation of HS-001, an Investigational Stem Cell-Derived Therapy for the Treatment of Advanced Heart Failure at the 71st Annual Meeting of the Japanese College of Cardiology
Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure, today announced that the case reports of two patients in the Phase 1/2 clinical trial (LAPiS Study) of HS-001 in combination with coronary artery bypass grafting surgery for advanced heart failure, was presented by the investigator at the 71st Annual Meeting of the Japanese College of Cardiology (JCC) on September 9, 2023.
Heartseed Enters into induced Pluripotent Stem Cell Purification Patent License Agreement for Commercialization of Cell Therapy
Heartseed Inc. (CEO: Keiichi Fukuda) today announced that it has entered into a worldwide non-exclusive patent license agreement (“Agreement”) with an undisclosed biotech company (“Licensee”) for its Metabolic Selection technology, a proprietary platform used to selectively remove undifferentiated induced pluripotent stem cells (iPSCs).
Heartseed raises 2 billion JPY in series D funding to accelerate development of iPSC-derived stem cell therapy for heart failure
Heartseed (Heartseed Inc.), a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), today announced it has raised 2 billion JPY at Series D round, bringing its total financial backing to 10.2 billion JPY (approx. $74 million) since it was founded in 2015.
Heartseed Raises $37 Million in Series C Funding to Accelerate Development of iPSC-derived Stem Cell Therapy for Heart Failure
Heartseed, a Tokyo-based biotechnology company developing iPSC-derived cardiomyocytes for heart failure (HF), today announced it has raised 4 Billion-yen (approx. $37 Million) at Series C round, bringing its total financial backing to 8.2 Billion yen (approx. $75 Million) since its foundation in 2015.
